Physician profile
Ciro A Ciccarelli
NPI 1548243579
$12,069.12
in general payments reported to CMS, 2019-2025
32 companies · $1,705 in 2025
The $1,705 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,841 · 2020: $1,302 · 2021: $1,785 · 2022: $2,116 · 2023: $1,880 · 2024: $1,441 · 2025: $1,705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,766 · Education: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,765.53 |
| Education | $259.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,035.14 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $2,992.45 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,416.42 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $708.43 | 2019-2025 | Dupixent |
| Amgen INC. | $545.44 | 2021-2025 | Tezspire |
| Philips North America LLC | $392.92 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Mylan Specialty L.P. | $359.37 | 2019-2024 | Yupelri |
| Electromed, INC. | $323.28 | 2019-2025 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $220.36 | 2019-2023 | Opsumit, Uptravi |
| Inspire Medical Systems, INC. | $219.81 | 2025 | Inspire |
| Grifols USA, LLC | $178.62 | 2019-2024 | Prolastin-C Liquid |
| Genzyme Corporation | $174.93 | 2019-2023 | |
| Genentech USA, INC. | $173.81 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $159.93 | 2022-2023 | Ingrezza |
| Advanced Respiratory, INC | $156.21 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $150.16 | 2025 | Arikayce, Brinsupri |
| Mallinckrodt Hospital Products INC. | $128.26 | 2021-2023 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $103.06 | 2020-2022 | |
| Baxter Healthcare | $98.21 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Covidien LP | $97.11 | 2019 | |
| Circassia INC. | $63.75 | 2019 | |
| Olympus America INC. | $60.70 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $54.79 | 2022 | |
| United Therapeutics Corporation | $53.21 | 2021-2022 | |
| Verona Pharma, INC. | $46.99 | 2025 | Ohtuvayre |
| Avanir Pharmaceuticals, INC. | $42.05 | 2021 | |
| Gilead Sciences, INC. | $35.24 | 2021 | |
| Merck Sharp & Dohme LLC | $20.61 | 2022 | |
| Viatris Specialty LLC | $17.99 | 2025 | Yupelri |
| Shire North American Group INC | $14.39 | 2019 | |
| Pulmonx Corporation | $13.88 | 2020 | |
| Paratek Pharmaceuticals, INC. | $11.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ciro Ciccarelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.